We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
CMP Pharma and Kiel Laboratories Sign Development Agreement
News

CMP Pharma and Kiel Laboratories Sign Development Agreement

CMP Pharma and Kiel Laboratories Sign Development Agreement
News

CMP Pharma and Kiel Laboratories Sign Development Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "CMP Pharma and Kiel Laboratories Sign Development Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

CMP Pharma and Kiel Laboratories have signed an agreement to develop, seek regulatory approval, and commercialize two new prescription drugs.

The first drugs will be directed at the general population with special emphasis on the geriatric market, followed by a product to be directed at the pediatric market.

While both drugs already exist as FDA approved solid dosage forms, CMP will be filing NDAs to obtain approval for an alternate liquid dosage form.

Commenting on the agreement, Gerald Sakowski, CEO of CMP Pharma, said, “These two products are excellent complements to our line of niche specialty pharmaceutical products. This is another chapter in our long history of developing stable, ready-to-use liquid dosage forms that make life easier on the consumer, the physician, and the pharmacist.”

Advertisement